Skip to content

Study · In vitro (cells) · 2010

3 results

Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.

Zatelli MC, Minoia M, Martini C, Tagliati F, Ambrosio MR, Schiavon M, Buratto M, Calabrese F, Gentilin E, Cavallesco G, Berdondini L, Rea F, degli Uberti EC

Endocrine-related cancer28 Jul 2010Cited by 49 (Europe PMC)

PMID20554786 (opens in a new tab)DOI10.1677/erc-10-0097 (opens in a new tab)PepBankPUB-20554786
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Efficacy outcome

    In primary human bronchial carcinoid cultures, adding pasireotide to everolimus had no additive effect on cell viability versus everolimus alone.

    In plain wordsIn cells from human bronchial carcinoids, pasireotide added no cell viability effect to everolimus alone.

    Peptide
    Pasireotide
    Outcome
    No significant changeCell viability
    Study

    humann: not reported in source

    primary bronchial carcinoid cultures
    Comparator
    everolimus alone
    Outcome group
    Tumor growth · Cancer
    Studied dose
    10 nM · 48 hAs given in this study (human).

    Source sentences

    Summary
    Cotreatment with SOM230 did not exert additive effects on cell viability and secretory activity.
    2 context sentences
    Summary · context
    We collected 24 BCs that were dispersed in primary cultures, treated without or with 1 nM-1 muM everolimus, 10 nM SOM230 (pasireotide, a somatostatin receptor multiligand), and/or 50 nM IGF1.
    Summary · context
    Cell viability was evaluated after 48 h, and chromogranin A (CgA) as well as vascular endothelial growth factor (VEGF) secretion was assessed after 8 h incubation.
  2. 02LabIn vitro (cells)Efficacy outcome

    In primary human bronchial carcinoid cultures, adding pasireotide to everolimus had no additive effect on chromogranin A secretion versus everolimus alone.

    In plain wordsIn human bronchial carcinoid cells, adding pasireotide did not further change chromogranin A secretion compared with everolimus alone.

    Peptide
    Pasireotide
    Outcome
    No significant changeChromogranin A secretion
    Study

    humann: not reported in source

    primary bronchial carcinoid cultures
    Comparator
    everolimus alone
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    10 nM · 8 hAs given in this study (human).

    Source sentences

    Summary
    Cotreatment with SOM230 did not exert additive effects on cell viability and secretory activity.
    2 context sentences
    Summary · context
    We collected 24 BCs that were dispersed in primary cultures, treated without or with 1 nM-1 muM everolimus, 10 nM SOM230 (pasireotide, a somatostatin receptor multiligand), and/or 50 nM IGF1.
    Summary · context
    Cell viability was evaluated after 48 h, and chromogranin A (CgA) as well as vascular endothelial growth factor (VEGF) secretion was assessed after 8 h incubation.
  3. 03LabIn vitro (cells)Efficacy outcome

    In primary human bronchial carcinoid cultures, adding pasireotide to everolimus had no additive effect on VEGF secretion versus everolimus alone.

    In plain wordsIn human bronchial carcinoid cells, adding pasireotide did not further change VEGF secretion compared with everolimus alone.

    Peptide
    Pasireotide
    Outcome
    No significant changeVEGF secretion
    Study

    humann: not reported in source

    primary bronchial carcinoid cultures
    Comparator
    everolimus alone
    Outcome group
    Receptor activity and mechanism · Cancer
    Studied dose
    10 nM · 8 hAs given in this study (human).

    Source sentences

    Summary
    Cotreatment with SOM230 did not exert additive effects on cell viability and secretory activity.
    2 context sentences
    Summary · context
    We collected 24 BCs that were dispersed in primary cultures, treated without or with 1 nM-1 muM everolimus, 10 nM SOM230 (pasireotide, a somatostatin receptor multiligand), and/or 50 nM IGF1.
    Summary · context
    Cell viability was evaluated after 48 h, and chromogranin A (CgA) as well as vascular endothelial growth factor (VEGF) secretion was assessed after 8 h incubation.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.